Arecor Ltd

Arecor Ltd

Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.

Telephone: +44 (0)1223 426 060
Address: Chesterford Research Park, Little Chesterford, Saffron Walden
Postcode: CB10 1XL
Country: United Kingdom
Website: http://www.arecor.com
Membership type:Corporate 6-20 (£250+VAT pa)

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

Arecor secures £6m investment for clinical development of its diabetes portfolio

Arecor Ltd, the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

10 September 2018Read in full

Arecor to give a short course and present at the Bioprocessing Summit, 13th-17th August 2018

Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.

9 August 2018Read in full

Arecor successfully defends a key European polysaccharide vaccine patent

Arecor Ltd, the UK-based leading formulation technology company focused on developing superior biopharmaceuticals and vaccines via its innovative formulation technology, is pleased to announce the successful outcome to its opposition proceedings at the European Patent Office in relation to a key patent of the company’s broad portfolio.

3 July 2018Read in full

Arecor announces superfast insulin data presentations at ADA scientific sessions

Arecor Ltd , the UK-based leading formulation technology company, today announces that its abstract supporting the application of its proprietary Arestat™ technology platform to enable a superfast insulin product has been accepted for a poster presentation at the upcoming American Diabetes Association (ADA) 78th Scientific Sessions, from June 22 - 26, 2018 in Orlando, FL, USA.

22 June 2018Read in full

Arecor secures grant to advance co-formulation of critical pharmaceutical products

Innovate UK grant of nearly £1 million will be used to significantly advance Arecor’s proprietary co-formulation platform in the development of diabetes therapies that meet critical patient unmet needs.

18 June 2018Read in full

Arecor at World Congress’ Biologics Formulation and Drug Delivery Technologies Summit

Arecor Limited, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to announce its participation at The World Congress’ Biologics Formulation and Drug Delivery Technologies Summit, on 21st and 22nd May 2018, at the Hilton Hotel, Boston, Massachusetts, USA.

15 May 2018Read in full

Arecor launches new website

Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce the launch of its new website.

10 January 2018Read in full

European patent on the horizon for Arecor’s proprietary technology

Arecor Ltd is pleased to announce the European Patent Office (EPO) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies such as trastuzumab or ustekinumab or fusion proteins such as abatacept.

8 January 2018Read in full

Arecor and JDRF announce successful pre-clinical development of diabetes treatment

Arecor and JDRF announce the successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes.

4 January 2018Read in full

Arecor’s vaccine stabilising formulation technology helps combat livestock diseases

Arecor Ltd, a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, ArestatTM, is pleased to announce that the Company, in partnership with GALVmed, has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.

8 December 2017Read in full

  1. 1
  2. 2
  3. 3
  4. 4